country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-149392

Copy Link Print Information

HBV-IN-35

HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC₅₀: 100 nM and 400 nM respectively).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₂₂H₂₃F₅N₄O
Molecular Weight:454.44

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

HBV-IN-35 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC₅₀: 100 nM and 400 nM respectively)^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
AML12	CC₅₀	>50 μM Compound: 88	Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37499290]

Chemical Information

Molecular Weight 454.44
Formel C₂₂H₂₃F₅N₄O
SMILES

O=C(NC1=CC(C(F)F)=C(F)C=C1)N2C(CN3CCC(F)(F)CC3)CNC4=C2C=CC=C4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hwang N, et al. Identification of novel tetrahydroquinoxaline derived phenyl ureas as modulators of the hepatitis B virus nucleocapsid assembly. Eur J Med Chem. 2023 Jul 17;259:115634. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen